STATEX TABLET 25MG

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

MORPHINE SULFATE

Tilgjengelig fra:

PALADIN LABS INC.

ATC-kode:

N02AA01

INN (International Name):

MORPHINE

Dosering :

25MG

Legemiddelform:

TABLET

Sammensetning:

MORPHINE SULFATE 25MG

Administreringsrute:

ORAL

Enheter i pakken:

100

Resept typen:

Narcotic (CDSA I)

Terapeutisk område:

OPIATE AGONISTS

Produkt oppsummering:

Active ingredient group (AIG) number: 0104545005; AHFS:

Autorisasjon status:

CANCELLED POST MARKET

Autorisasjon dato:

2023-02-20

Preparatomtale

_Product Monograph _
_ _
_STATEX_
_®_
_ (morphine sulfate tablets) _
_Page 1 of 31_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
STATEX®
Morphine sulfate tablets
Tablets, 5 mg, 10 mg, 25 mg, 50 mg, Oral
Opioid Analgesic
N02AA01
Paladin Labs Inc.
100 Alexis Nihon Blvd., Suite 600
Saint-Laurent, Quebec
H4M 2P2
Date of Initial Authorization:
December 04, 1985
Date of Revision:
June 28, 2023
Version: 7.0
Submission Control Number: 271305
_ _
_Product Monograph _
_ _
_STATEX_
_®_
_ (morphine sulfate tablets) _
_Page 2 of 31_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Abuse and Misuse
06/2023
7 WARNINGS AND PRECAUTIONS, Neurologic
06/2023
7 WARNINGS AND PRECAUTIONS, Respiratory
06/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND ADMINISTRATION
.................................................................................
6
4.1
Dosing Considerations
............................................................................................
6
4.2
Rec